Department of Radiation Oncology, University of Pennsylvania, Philadelphia, USA.
Varian Medical Systems Inc, Palo Alto, CA, USA.
Radiat Oncol. 2023 Sep 2;18(1):144. doi: 10.1186/s13014-023-02340-2.
Adaptive radiotherapy (ART) was introduced in the late 1990s to improve the accuracy and efficiency of therapy and minimize radiation-induced toxicities. ART combines multiple tools for imaging, assessing the need for adaptation, treatment planning, quality assurance, and has been utilized to monitor inter- or intra-fraction anatomical variations of the target and organs-at-risk (OARs). Ethos™ (Varian Medical Systems, Palo Alto, CA), a cone beam computed tomography (CBCT) based radiotherapy treatment system that uses artificial intelligence (AI) and machine learning to perform ART, was introduced in 2020. Since then, numerous studies have been done to examine the potential benefits of Ethos™ CBCT-guided ART compared to non-adaptive radiotherapy. This review will explore the current trends of Ethos™, including improved CBCT image quality, a feasible clinical workflow, daily automated contouring and treatment planning, and motion management. Nevertheless, evidence of clinical improvements with the use of Ethos™ are limited and is currently under investigation via clinical trials.
自适应放疗(ART)于 20 世纪 90 年代末引入,旨在提高治疗的准确性和效率,最大限度地减少放射性毒性。ART 结合了多种成像工具,用于评估适应性需求、治疗计划、质量保证,并已用于监测靶区和危及器官(OAR)的分次内或分次间解剖学变化。Ethos™(Varian Medical Systems,加利福尼亚州帕洛阿尔托)是一种基于锥形束计算机断层扫描(CBCT)的放疗治疗系统,它使用人工智能(AI)和机器学习来进行 ART,于 2020 年推出。此后,已经进行了许多研究来检查 Ethos™ CBCT 引导的 ART 与非自适应放疗相比的潜在益处。本综述将探讨 Ethos™ 的当前趋势,包括改善的 CBCT 图像质量、可行的临床工作流程、每日自动勾画和治疗计划以及运动管理。然而,使用 Ethos™ 带来临床改善的证据有限,目前正在通过临床试验进行调查。